Key result
Hodgkin lymphoma treatment is linked to higher CVD and secondary cancer mortality at 20 years.
Why the study?
Life expectancy of Hodgkin lymphoma survivors is reduced by late adverse events including second malignant neoplasms and cardiovascular diseases, but detailed cause-specific mortality data are needed.
What are the long-term causes of death, specifically regarding second malignant neoplasms and cardiovascular diseases, in survivors of Hodgkin lymphoma?
Cohort (n=1,435)
Yes
What are the long-term causes of death, specifically regarding second malignant neoplasms and cardiovascular diseases, in survivors of Hodgkin lymphoma?
p-value: p=<.001
Hodgkin lymphoma survivors face a long-term increased risk of mortality from cardiovascular diseases and second malignant neoplasms, highlighting the need for prolonged surveillance.
PURPOSE: Hodgkin lymphoma (HL) is classified as the first malignancy to be cured by a combination of chemotherapy and radiotherapy. However, the life expectancy of HL survivors is hampered by the occurrence of late adverse events, including second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs). PATIENTS AND METHODS: We investigated the causes of death in a cohort of 1,435 patients over age 15 years treated at 18 different public cancer centers in Chile. RESULTS: < .001). HL was the main cause of death in the first 10 years after treatment, whereas SMN and CVD risk peaked 10-15 years and remained raised for 30 years or longer. Cumulative incidence of deaths (CIDs) due to SMNs resulted significantly higher in patients treated with cyclophosphamide, vincristine, procarbazine, prednisone (MOPP)/MOPP-like regimens over doxorubicin, bleomycin, vinblastine, dacarbazine. CIDs due to CVDs increased from 0.4 to 4.1 at 5 and 20 years, respectively. CONCLUSION: HL survivors continue to have a reduced life expectancy due to an increased risk of dying of SMNs and/or CVDs, although it was lower among patients treated in the most recent calendar period studied (2002-2014).
No takes yet. Share an insight, caveat, or question.
Cabrera et al. (2025) conducted a cohort in Hodgkin lymphoma (n=1,435). Hodgkin lymphoma treatment vs. Unexposed/reference population (implied) was evaluated on Causes of death (including second malignant neoplasms and cardiovascular diseases) (p=<.001). Hodgkin lymphoma treatment was associated with increased long-term mortality from second malignant neoplasms and cardiovascular diseases, with CVD death incidence reaching 4.1 at 20 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: